Leading Companies
- In September 2022 Merck Animal Health announced the donation of five million doses of its NOBIVAC rabies vaccine to help eliminate canine-mediated rabies through the Afya program. Mission Rabies has now vaccinated nearly two million dogs through Merck Animal Health’s Afya program.
- In July 2020, Elanco, a U.S.-based animal health and pharmaceutical company, announced the acquisition of Bayer’s animal health division, a German-based healthcare company, for $7.6 billion to expand its animal healthcare portfolio.
- In April 2020, Boehringer Ingelheim, a U.K. company, collaborated with VetHelpDirect, which offered all U.K. veterinary practices free access to an online video consultation platform for a period of three months during the pandemic. By offering an alternative to face-to-face consultation, the online platform is a means of continuing care for animals while protecting both clients and staff from the spread of COVID-19.
- In October 2020, Zoetis, a global animal health company, announced the launch of Versican Plus Bb Oral, the first oral vaccine for dogs in Europe. The vaccine provides robust, long-lasting protection against Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC), with easy oral administration.
Global Companion Animal Vaccine Market : Key Players
Major players operating in the global companion animal vaccine market include Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Ceva Ltd., Merck & Co. Inc., Virbac, Zoetis Inc., HIPRA, Biogénesis Bago, Ourofino Animal Health, Croda International Plc, KM Biologics, Indian Immunological Ltd., Sinovac, Kyoto Biken Laboratories, Inc., HESTER BIOSCIENCES LIMITED, Calier, Bioveta, a.s